If approved, Perrigo’s Opill could be the first-ever nonprescription birth control pill.
The FDA has rescheduled a joint meeting of the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee for May 9 & 10, 2023, to review the Perrigo’s application for Opill. The nonprescription Opill consists of 0.075 mg norgestrel and is a progestin-only daily birth control pill, which is also referred to as a mini pill or non-estrogen pill. The prescription Opill is not currently marketed.
HRA Pharma, a Perrigo company, had submitted its application in July 2022, and the advisory committee meeting was originally scheduled for Nov. 18, 2022, but in October 2022, the FDA postponed the meeting in order to review additional information requested related to the Opill Rx-to-OTC switch.
“The days of the current prescription requirement – a barrier that disproportionately impacts Black, Indigenous, Latina/x, Asian Americans, Native Hawaiian and Pacific Islander communities, LGBTQ+ folks, young people, people with disabilities, and those working to make ends meet – are numbered,” Victoria Nichols, project director of Free the Pill, a project of Ibis Reproductive Health, said in a statement.
Over-the-counter birth control has support from major medical organizations including the American College of Obstetricians and Gynecologists, the American Medical Association and the American Academy of Family Physicians.
“Over 100 countries round the world currently provide oral contraceptive pills over the counter without a prescription. The AAFP supports over-the-counter access to oral contraception without a prescription,” the American Academy of Family Physicians said in a statement.
Officials from the American College of Obstetricians and Gynecologists said access barriers are one reason why women may not use contraception. They support OTC use without age or cost restrictions. One national survey of 1,385 women reported that among the 68% of people who had ever tried to obtain a prescription for hormonal contraception, 29% had problems accessing the initial prescription or refills.
Perrigo has indicated the application includes an indication that has no age restrictions.
For Rx-to-OTC switches, the FDA requires sponsors to conduct two pivotal trials that demonstrate consumers can understand the label and how to use the drug safely.
While Perrigo has not released its data, a study published online last year in Perspectives on Sexual and Reproductive Health found that study participants understood the label information required for safe use without clinician involvement. Investigators surveyed 63 adults and teens aged 12 to 49 years of age. They found that 10 of the 11 primary endpoints were understood by more than 95% of participants. The remaining primary endpoint on use with prior blood clots was understood by 89% of participants.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More